A5027370869- Silicon Effects in Agriculture
- Platelet Disorders and Treatments
- Aluminum toxicity and tolerance in plants and animals
- Hemophilia Treatment and Research
- Banana Cultivation and Research
- Geochemistry and Elemental Analysis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood properties and coagulation
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pharmaceutical studies and practices
- Erythropoietin and Anemia Treatment
- Peroxisome Proliferator-Activated Receptors
- Inorganic Fluorides and Related Compounds
- Lipid metabolism and biosynthesis
- Antiplatelet Therapy and Cardiovascular Diseases
- Vitamin K Research Studies
- Plant biochemistry and biosynthesis
- Boron Compounds in Chemistry
- Crystallography and molecular interactions
- Blood groups and transfusion
- Clinical Laboratory Practices and Quality Control
LFB (France)
2007-2024
UCLouvain
2005-2008
Université Paris-Sud
1997
Factor XI (FXI)-deficient patients may develop excessive bleeding after trauma or surgery. Replacement therapy should be considered in high-risk situations, especially when FXI levels are below 20 IU dL(-1) . HEMOLEVEN is a human plasma-derived factor concentrate available France since 1992, but there few data regarding its use by physicians. This prospective study assessed the use, efficacy and safety of common clinical practice. was evaluated FXI-deficient 13 French centres 3-year...
Background A triple-secured plasma-derived von Willebrand factor (pdVWF) almost devoid of VIII (FVIII):WILFACTIN®, was approved in France 2003, and then other countries for the treatment patients with disease (VWD). Objective To investigate long-term safety efficacy product real-life over first 5 post-approval years. Patients/Methods This prospective, observational, national post-marketing study (PMS) enrolled all ages VWD types. Patients were observed up to 3 years treated one or more...
Aims The pharmacokinetics (PK) of a triple‐secured fibrinogen concentrate (FC) was assessed in patients ≥40 kg by noncompartmental analysis over period 14 days with multiple blood samples. Limited PK time point assessments children lead to consideration using Bayesian estimation for paediatric data. objectives were (i) define the population FC afibrinogenaemia; (ii) detect age‐ and body weight‐related differences consequences dose adjustment. Methods A model built plasma activity data...
To date, the use of a fibrinogen concentrate (FC) administered in children with inherited deficiency is poorly documented. Treatment modalities may differ from those adults. The aim this study was to investigate pharmacokinetics (PK), efficacy (bleeding/surgery) and safety triple-secured FC (FibCLOT, LFB, France) young patients aged 12 years or less. This prospective, non-comparative, multicentre, phase 2-3 study. Estimated PK parameters were based on population modelling. Target levels 1.2...
Introduction Von Willebrand factor (VWF) replacement therapy is commonly used in the treatment of patients with von Disease (VWD) who do not respond to or cannot use desmopressin. While its effectiveness adults well-known, it important investigate usage paediatric population, as a key element clinical trial programme VWF product because children may differently treatment.
Abstract Background A plasma-derived factor VIII product (pdFVIII; Factane 100 or 200 IU/mL) and a von Willebrand (pdVWF; Wilfactin are approved for replacement therapy by intravenous bolus injections in hemophilia (HA) disease (VWD), respectively. However, situations requiring intensive treatment, continuous infusion (CI) may be desirable to better control target plasma levels. Aim To evaluate the perioperative hemostatic efficacy safety of these concentrates administered CI. Methods Three...
Plasma-derived von Willebrand factor (VWF) (Wilfactin®, LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults adolescents with disease (VWD). Replacement therapy paediatric patients is a key element the clinical trial programme.Patients aged <6 years severe VWD were enrolled multinational, open-label study to evaluate vivo recovery Wilfactin®, its efficacy preventing treating bleeding episodes during surgery. Overall haemostatic based on 4-point scale...